Oblique Therapeutics AB – Trademark Portfolio
Entity Type: 99
Oblique Therapeutics AB has 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO). Notable registered marks include OBLIQUE THERAPEUTICS. The portfolio includes 1 registered trademark. Filings span 4 Nice Classification classes, led by Class 42 (Computer & Scientific) and Class 9 (Computers & Electronics). This trademark owner is based in 413 46 Göteborg.
Arvid Wallgrens Backe 20
413 46 Göteborg 41346 , SE
Showing of trademarks Trademarks
Trademark Classifications
Oblique Therapeutics AB's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Oblique Therapeutics AB have?
Oblique Therapeutics AB has 4 U.S. trademarks filed with the USPTO. Of these, 1 registered, 3 abandoned.
What trademark classes does Oblique Therapeutics AB file in?
Oblique Therapeutics AB files trademarks across 4 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 9 (Computers & Electronics), Class 5 (Pharmaceuticals), Class 40 (Treatment & Processing). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Oblique Therapeutics AB's most well-known trademarks?
Oblique Therapeutics AB's registered trademark portfolio includes well-known marks such as OBLIQUE THERAPEUTICS. These are among 1 currently registered trademark in the portfolio.
What is Oblique Therapeutics AB's trademark registration success rate?
Oblique Therapeutics AB has a 25% trademark registration rate, with 1 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.